Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enfin-Forte is a high-dose neurotropic vitamin complex containing thiamine (Vitamin B1), pyridoxine (Vitamin B6), and cyanocobalamin (Vitamin B12). Developed by Grand Medical Group, it is primarily indicated for the treatment of various neurological disorders, including neuralgia, neuritis, radicular syndrome, and polyneuropathy (such as diabetic or alcoholic neuropathy). The combination of these B-complex vitamins acts synergistically to support the metabolism of the central and peripheral nervous systems. Thiamine serves as a cofactor for enzymes involved in carbohydrate metabolism and nerve impulse conduction; pyridoxine is essential for the synthesis of neurotransmitters like dopamine, serotonin, and GABA; and cyanocobalamin is crucial for myelin sheath formation and nucleic acid synthesis. The "Forte" designation typically refers to the oral tablet formulation, which is often used for maintenance therapy following acute treatment with injectable forms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamine + pyridoxine + cyanocobalamin (Grand Medical Group AG).